Retatrutide targets GLP1R, GIPR, and glucagon receptor simultaneously, making fatigue and blood sugar side effects cancel out elegantly.
Key Takeaways
Semaglutide hits only GLP1R; tirzepatide adds GIPR; retatrutide adds glucagon receptor on top, creating a triple agonist.
Glucagon drives energy expenditure but raises blood sugar and promotes fat storage via cortisol; GLP-1 counteracts both downsides.
The synergy is structural: glucagon and GLP-1 share blob-shaped peptide similarity, which is why GLP1R has weak affinity for glucagon.
Extended half-life is achieved by attaching fatty acid chains that are slowly cleaved, spacing out receptor activation like a slow IV drip.
Muscle loss, thyroid tumor risk (observed in rodents), and slowed gut transit affecting co-administered drug absorption remain open concerns.
Hacker News Comment Review
Early first-person reports on retatrutide are notably positive, with users describing reduced appetite and improved food preferences rather than just suppression.
Discussion is thin but curiosity is high around whether the glucagon mechanism produces a mood or energy lift beyond appetite effects, which the article flags as unconfirmed.
Notable Comments
@mchusma: Personal user reporting retatrutide produces a desire to eat healthier, not just less, across four known users including himself.
